These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2634542)

  • 1. [In vitro experimental expansion and induction of LAK cell of lymphocytes from human carcinomatous ascites].
    Li DJ
    Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):433-6. PubMed ID: 2634542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y; Umesaki N
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):611-8. PubMed ID: 1856521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
    Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
    Ebihara T; Koyama S
    Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
    Chao TY; Hwang WS; Yeh MY
    Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The rapid activation of human LAK cells and their inhibition on ovarian cancer at the advanced stage].
    Song YF; Zhao YN; Li J
    Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):332-5, 381. PubMed ID: 8001405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach to the treatment of malignant effusion.
    Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
    Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell].
    Meng YG; Fu CY; Wang YZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
    Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
    Guo Y; Xing Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
    Guo YS; Xing ZL
    Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.